NEW YORK, April 28 (Reuters) - Dendreon Corp’s DNDN.O shares swung wildly on Tuesday, at one time rising 16 percent and then subsequently sliding more than 60 percent as investors braced for data from a study involving a …
I like smarter guys than me to do the earlier heavy lifting. So I look for good successful investors who are also buying the stock. When it comes to DNDN that’s easy. According to recent filing there are at least 4 super billionaire investors …
Shares of Dendreon are off over 2% today despite an overall flat market. And down 12% in the past week despite the S&P being down about 0.4%. But even more importantly, shares of DNDN, currently at 34 and change are off 23 points from …
That move prompted at least six brokerages to cut their rating on Dendreon s stock. The company has pointed to reimbursement concerns and delayed physician adoption as the primary reasons why Provenge s sales growth has …
Dendreon Corporation (NASDAQ ... We checked around to find out if one could borrow DNDN stock. We are told there is a -9.95% rebate on anything above 200,000 shares. Is there hope? Last quarter, DNDN announced more data analysis …
Shares of Dendreon surged Thursday after the company said sales of its prostate-cancer therapy Provenge continued to grow in the fourth quarter. Seattle-based Dendreon said sales of Provenge rose to $82 million in the fourth quarter. …
NEW YORK (Reuters) - A lightening fast sell-off of shares of biotech company Dendreon last April is drawing scrutiny from U.S. securities regulators and the independent monitor assigned to keep tabs on those regulators, said people …
J.P. Morgan (NYSE: JPM) has a $46 price target on the shares. During the last 52 weeks, Dendreon's stock has traded from a low of $2.55 to a high of $33.85. There are few signs that the momentum in this name will not continue. If their …
Shares of the drugmaker Dendreon are plummeting in trading, a day after the company announced a restructuring that includes closing a Morris County manufacturing plant. The Seattle-based company saw its stock slide more than 22 …
The volatility of Dendreon's stock provides a fascinating insight into the allure of a new treatment modality, the bungles of the Provenge trials and the steely determination of the company to bring its first ever product to market. Dendreon's …